Revolutionary APIs are reshaping India’s pharmaceutical industry—Bioaltus Pharmaceuticals Pvt. Ltd. is leading the charge with innovation, quality, and patient-first solutions. With a focus on proven results and patient-centred solutions, Bioaltus is redefining what pharmaceutical excellence looks like in 2025.

Revolutionary APIs Backed by Science and Scale

Bioaltus’s API range is not just extensive—it’s revolutionary. The company has developed and optimized a portfolio that includes bilayer tablets, patterned release tablets, sustained-release tablets, pellet capsules, and tablet-in-capsule formulations. This diversity in dosage forms not only showcases their technological prowess but also reflects their patient-centric approach, aiming to improve compliance and therapeutic outcomes.

In the realm of Active Pharmaceutical Ingredients (APIs), Bioaltus has made significant strides. Their API portfolio includes critical compounds like Doxofylline, Levosulpiride, Bilastine, Teneligliptin, Flavoxate HCl, Febuxostat, Sertaconazole, Acebrophylline, Sevelamer HCl, Eberconazole, Fenofibrate, Luliconazole, Tadalafil, Olopatadine, Dapagliflozin, Dapoxetine HCl, Sitagliptin, Vildagliptin, and Praziquantel HCl. 

Proven Results Across Therapies and Technologies

What sets Bioaltus apart is not just the scale of manufacturing—but the outcomes their products deliver. These APIs are integral to the treatment of various conditions, ranging from respiratory disorders and gastrointestinal issues to metabolic syndromes and infectious diseases.

Beyond APIs, Bioaltus is also renowned for its production of pharmaceutical intermediates and fine chemicals. Compounds such as Isoxepac, Dioctyl Sodium Sulfosuccinate, N,N-Dimethyl Formamide Dimethyl Acetal, Glimepiride Sulfonamide, and 1,4-Methoxyl Phenyl Piperazine are among the key intermediates they manufacture. These substances are crucial in the synthesis of various therapeutic agents, underscoring Bioaltus’s role in the broader pharmaceutical supply chain.

Bioaltus’s commitment to quality is further exemplified by their adherence to stringent regulatory standards and their investment in cutting-edge research. Their manufacturing units are equipped with advanced technologies that facilitate the production of high-purity compounds, ensuring consistency and reliability in every batch. Moreover, their focus on continuous improvement and innovation positions them at the forefront of pharmaceutical advancements.

With revolutionary APIs, proven therapeutic results, and future-ready manufacturing, Bioaltus Pharmaceuticals is not just contributing to Indian pharma—it’s leading it. By combining innovation, regulatory excellence, and a patient-first approach, Bioaltus is poised to shape the next chapter of global healthcare.

To explore our complete API offerings or discuss partnership opportunities, visit our product portfolio or contact us today.